Sverige - svenska - Läkemedelsverket (Medical Products Agency)

norbrook laboratories (ireland) limited - amoxicillintrihydrat; kaliumklavulanat - tablett - 40 mg/10 mg - kaliumklavulanat 12,52 mg aktiv substans; amoxicillintrihydrat 45,91 mg aktiv substans; azorubin hjälpämne - amoxicillin och enzymhämmare - hund, katt

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

norbrook laboratories limited - amoxicillintrihydrat; kaliumklavulanat - tablett - 400 mg/100 mg - amoxicillintrihydrat 459 mg aktiv substans; kaliumklavulanat 119 mg aktiv substans - amoxicillin och enzymhämmare - hund

Europeiska unionen - svenska - EMA (European Medicines Agency)

elanco gmbh - monepantel - anthelmintics, - får - zolvix oral lösning är ett brett spektrum anthelmintic för behandling och kontroll av gastrointestinala nematodeinfektioner och associerade sjukdomar hos får inklusive lamm, hoggets, avelstammar och tackor. spectrum of activity includes fourth larvae and adults of: , haemonchus contortus*;, teladorsagia circumcincta*;, teladorsagia trifurcata*;, teladorsagia davtiani*;, trichostrongylus axei*;, trichostrongylus colubriformis;, trichostrongylus vitrinus;, cooperia curticei;, cooperia oncophora;, nematodirus battus;, nematodirus filicollis;, nematodirus spathiger;, chabertia ovina;, oesophagostomum venulosum. , * bland annat hämmade larver. det veterinärmedicinska läkemedlet är effektivt mot stammar av dessa parasiter som är resistenta mot (pro) bensimidazoler, levamisol, morantel, makrocykliska laktoner och h. contortusstammar som är resistenta mot salicylanilider.

Europeiska unionen - svenska - EMA (European Medicines Agency)

sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastiska medel - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. endast begränsade data finns tillgängliga om effekten och säkerheten för patienter som tidigare behandlats med monoklonala antikroppar inklusive rituximab eller patienter med refraktära mot tidigare rituximab plus kemoterapi. se avsnitt 5. 1 för ytterligare information. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituximab har visat sig minska risken för progression av ledskador mätt med röntgen och förbättra den fysiska funktionen, när det ges i kombination med metotrexat. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

uni-pharma kleon tsetis pharmaceutical laboratories s.a. - levotyroxinnatrium (hydrat) - tablett - 50 mikrogram - levotyroxinnatrium (hydrat) 56 mikrog aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

uni-pharma kleon tsetis pharmaceutical laboratories s.a. - levotyroxinnatrium (hydrat) - tablett - 62 mikrogram - levotyroxinnatrium (hydrat) 69 mikrog aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

uni-pharma kleon tsetis pharmaceutical laboratories s.a. - levotyroxinnatrium (hydrat) - tablett - 112 mikrogram - levotyroxinnatrium (hydrat) 125 mikrog aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

uni-pharma kleon tsetis pharmaceutical laboratories s.a. - levotyroxinnatrium (hydrat) - tablett - 100 mikrogram - levotyroxinnatrium (hydrat) 111 mikrog aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

uni-pharma kleon tsetis pharmaceutical laboratories s.a. - levotyroxinnatrium (hydrat) - tablett - 150 mikrogram - levotyroxinnatrium (hydrat) 168 mikrog aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

uni-pharma kleon tsetis pharmaceutical laboratories s.a. - levotyroxinnatrium (hydrat) - tablett - 13 mikrogram - levotyroxinnatrium (hydrat) 14 mikrog aktiv substans